In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

Its donanemab Alzheimer’s drug is seen as a ... These ratings could be tested as Eli Lilly reports earnings tomorrow, especially with investor focus locked on revenue from its blockbuster ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...

Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement of Biogen's first-to-market Aduhelm has made ...

Lilly has an Earnings ESP of -14.61% and a ... Sales of the new Alzheimer’s drug Kisunla (donanemab) are likely to have improved sequentially. Kisunla was approved in China in December 2024 ...

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate ...